Teal Health Raises $22 Million Ahead of a 2027 Coverage Mandate

Teal Health raised $22 million in a Series A round led by .406 Ventures, the company said Tuesday, timed to a January 2027 federal rule that will require most U.S. health plans to cover at-home cervical cancer screening with no cost to patients.

The round brings Teal's total funding to $45 million, meaning the company had raised roughly $23 million before this Series A, a figure Tuesday's announcement did not break down by earlier round. Participating investors include Emerson Collective, Forerunner, Serena Ventures and, as a new entrant, Japan-based MPower Partners.

What the Teal Wand does, and who cleared it

Teal's product is the Teal Wand, a self-collection device for HPV testing that a patient uses at home, paired with a telehealth visit, result delivery through a secure platform and a referral path if follow-up care is needed. The Food and Drug Administration authorized the device in 2025. Chief Executive and co-founder Kara Egan said the company built it "for all women, whether they are behind on their screening or coming due."

A mandate that has not happened yet

Starting in January 2027, federal guidelines will require most health plans to cover self-collected cervical cancer screening at no cost, the kind of regulatory date that turns a niche device into a covered benefit overnight. Teal's $22 million raise is modest against the size of that opening: the company is spending the 15 months before the mandate takes effect on a round smaller than many single-product seed rounds in enterprise software, betting operational readiness matters more than a larger war chest before the rule forces insurers to pay.

.406 Ventures partner Kathryn Taylor Reddy said Teal "is positioned to transform how millions of women receive essential preventive healthcare," a claim that rests on the mandate actually taking effect on schedule and on Teal's manufacturing and telehealth capacity scaling to meet it.

The screening gap in Teal's own numbers

Nearly one in three U.S. women are not current on cervical cancer screening, according to the figures Teal cited in its announcement. The company put the annual U.S. death toll from the disease at about 4,320; MedCity News cited an American Cancer Society projection of roughly 4,200 deaths for 2026, a gap of about 120 that neither outlet reconciled. Among people who have used the Teal Wand, the company said 59 percent were behind on screening before they did, nearly double the national rate.

MedCity News also reported that Aetna, Anthem, Cigna, Blue Cross Blue Shield and UnitedHealthcare already cover the Teal Wand for some members ahead of the 2027 mandate, and that Teal prices the test at $99 with insurance and $249 for self-pay patients without it.

1. U.S. women overall33 %
2. Teal Wand users before testing59 %

Source: Teal Health funding announcement, PR Newswire, accessed 2026-09-24

That gap is the company's argument for why its users are not a random sample of the insured population but a group the existing system was already missing, the same population the 2027 mandate is designed to reach. It is also the number Teal did not need investors to independently verify, since it comes from Teal's own user base rather than a claim about the broader market.

What happens before January 2027

Teal's announcement did not say how the $22 million will be split between manufacturing capacity, telehealth staffing and the sales effort needed to get health systems to adopt the Wand before the mandate arrives, and it did not disclose a valuation for the round. The company's next visible test is operational rather than clinical: whether it can scale distribution fast enough that the January 2027 coverage requirement finds a product already in health systems' hands rather than one still ramping up. Teal's raise follows a broader run of venture money into women's health data plays that have not yet turned a profit, including Evvy's Series B in fertility data and, on a different scale entirely, Forus's valuation tripling to $3 billion in four months.